Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II induction therapy with tislelizumab + docetaxel + cisplatin for initially unresectable locally advanced head and neck squamous cell carcinoma
ChiCTR2400087343Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, docetaxel and cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective response rate. Started Jul 2024; status: recruiting.
02
Drugs
tislelizumabdocetaxelcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400087343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087343.